Video

  • 20 June 2016

    BIO-Europe Spring 2016: RMI says it has USD 200 million already under management

    BIO-Europe Spring 2016: RMI says it has USD 200 million already under management

    EBD Group

    Maxim Gorbachev, a partner and portfolio manager at RusnanoMedInvest (RMI) speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio about Russia’s and Eastern Europe’s largest venture capital company, specializing in innovative developments in the field of pharmaceuticals and biotechnology. 

  • 22 June 2015

    Leonid Melamed: uncertainty period is the best time to make important tactical and strategical decisions

    Leonid Melamed: uncertainty period is the best time to make important tactical and strategical decisions

    June 25, 2015, Vedomosti newspaper office will host a FocusForum Conference in Moscow with a leading participation of Leonid Melamed, the Chairman of Team Drive, member of the Board of Directors of NovaMedica, RMI Partners and Doctor Ryadom. The conference’s goal is to gather experts and share ideas and valuable experience in the time of business challenges. In his video interview to Vedomosti, Leonid explained his vision of the company management tasks in the period of uncertainty. 

  • 16 October 2014

    Dr. Evgeny Zaytsev, Managing Partner, RMI Partners: Exits in biotech usually have a very long tail of payments

    Dr. Evgeny Zaytsev, Managing Partner, RMI Partners: Exits in biotech usually have a very long tail of payments

    As part of the Panel Discussion “Optimal Strategies and Exit Models for Venture Investors” held during 3rd Moscow International Forum for Innovative Development “Open Innovations” Evgeny Zaytsev shared his experience of various exit models from venture investments in biotech.

  • 23 May 2014

    SPIEF2014. Leonid Melamed: Apparently, the one, who shall benefit from the development of public-private partnerships, is the patient

    SPIEF2014. Leonid Melamed: Apparently, the one, who shall benefit from the development of public-private partnerships, is the patient

    In general terms, engagement of private companies in the healthcare system on a competitive basis shall result in the price optimization and improvement of the quality of medical services provided and pharmaceuticals delivered to patients, Leonid Melamed, Chairman of the Board, Team Drive; Member of the Board of Directors, RusnanoMedInvest and NovaMedica said on Friday at St. Petersburg SPIEF2014.

  • 12 February 2013

    Brian Dovey, Domain Associates LLC -  speaking about VC/Rusnanotech 2011

    Brian Dovey, Domain Associates LLC - speaking about VC/Rusnanotech 2011

    Brian Dovey, Partner, Domain Associates LLC (one of the first venture capital firms to exclusively invest in the life sciences sector) -  speaking about VC (Rusnanotech 2011)

  • 21 June 2012

    St. Petersburg International Economic Forum

    St. Petersburg International Economic Forum

    Leonid Melamed: Isolated oases of narrowly focused innovation in life sciences are not the way forward for Russia and represent a temporary fix at best – what is needed to drive truly transformational change are fully-integrated life sciences innovation clusters supported by an ecosystem of research and development, finance and other key success factors and specialized skill sets

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica launched Technology Center to develop innovative drugs

    NovaMedica launched Technology Center to develop innovative drugs

    NovaMedica, a Russian pharmaceutical company (RUSNANO portfolio company), started operation of the Technology Center designed for the development and pilot production of innovative drug products. It comprises a complex of R&D laboratories and production areas with technological capabilities which are unique for the Russian pharmaceutical industry and one of the best in Europe. Crucial tasks of the Technology Center are to develop the advanced oral medical products of different pharmacotherapeutic groups, including those to treat cardiovascular and gastroenterological diseases, central nervous system diseases, and to create painkillers drugs of the new generation.  

All news